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ARTICLE
Methylated DNMT1 and E2F1 are targeted for
proteolysis by L3MBTL3 and CRL4DCAF5 ubiquitin
ligase
Feng Leng1,2, Jiekai Yu1, Chunxiao Zhang1,2, Salvador Alejo 1, Nam Hoang1, Hong Sun1, Fei Lu 2 &
Hui Zhang 1
Many non-histone proteins are lysine methylated and a novel function of this modiﬁcation is
to trigger the proteolysis of methylated proteins. Here, we report that the methylated lysine
142 of DNMT1, a major DNA methyltransferase that preserves epigenetic inheritance of DNA
methylation patterns during DNA replication, is demethylated by LSD1. A novel methyl-
binding protein, L3MBTL3, binds the K142-methylated DNMT1 and recruits a novel
CRL4DCAF5 ubiquitin ligase to degrade DNMT1. Both LSD1 and PHF20L1 act primarily in S
phase to prevent DNMT1 degradation by L3MBTL3-CRL4DCAF5. Mouse L3MBTL3/MBT-1
deletion causes accumulation of DNMT1 protein, increased genomic DNA methylation, and
late embryonic lethality. DNMT1 contains a consensus methylation motif shared by many
non-histone proteins including E2F1, a key transcription factor for S phase. We show that the
methylation-dependent E2F1 degradation is also controlled by L3MBTL3-CRL4DCAF5. Our
studies elucidate for the ﬁrst time a novel mechanism by which the stability of many
methylated non-histone proteins are regulated.
DOI: 10.1038/s41467-018-04019-9 OPEN
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Lysine-speciﬁc methylation is a major protein modiﬁcationand extensive research has established the key roles of var-ious methylated lysine residues at the amino-terminal
regions of histones in modulating chromatin structure and gene
expression1, 2. Lysine methylations in histones, together with
other histone modiﬁcations, constitute the “histone code” that
acts in a combinatorial or sequential fashion to specify unique
downstream function3. For example, extensive studies have
established that the trimethylation at lysine 4 in histone H3
(H3K4) typically deﬁnes a “permissive” chromatin structure that
allows active transcription, whereas trimethylations at lysines 9
and 27 in histone H3 (H3K9 and H3K27) are usually associated
with repressive chromatin structure that suppresses gene
expression4. Methylation of lysine 20 in histone H4 (H4K20)
plays a critical role in regulating genome stability in response to
DNA damage and replication stress5. Various mono-, di-, and
trimethylated lysine residues in histones usually provide speciﬁc
protein recognition modules that are “read” by distinct
methylation-binding proteins, such as proteins with the Chromo-,
Tudor-, MBT-, or PHD-domains, to recruit effector proteins such
as transcription factors or chromatin modulators to regulate
chromatin organization and gene activities1, 4, 6, 7.
Emerging evidence indicates that many non-histone proteins
are also methylated at speciﬁc lysine residues to regulate their
activity or protein stability8, 9. The tumor suppressor protein p53
was the ﬁrst non-histone protein that is found to be mono-
methylated at lysine 372 (K372) by SET7 (KMT7, SETD7, SET9,
or SET7/9), a methyltransferase that was originally identiﬁed for
its methylation activity toward H3K4 of histone H38, 10. Sub-
sequent reports showed that many non-histone proteins,
including DNA (cytosine-5)-methyltransferase 1 (DNMT1),
LIN28A, E2F1, NFκB/RelA, ERα, GLI3, RB, FOXO3, TAF10, and
STAT3, are also methylated at speciﬁc lysine residues by SET7 in
embryonic stem cells and various other cells8, 9, 11–13. SET7 can
also methylate a large number of non-histone proteins at speciﬁc
lysine residues in vitro11, suggesting it may have additional tar-
gets in vivo. While the function and regulation of these methy-
lation events in non-histone proteins remain largely
uncharacterized, accumulating evidence indicates that methyla-
tion of lysine residues by SET7 on a group of non-histone pro-
teins, such as DNMT1, E2F1, NFκB/RelA, FOXO3, and STAT3,
triggers the proteolytic destruction of these modiﬁed proteins14–
18.
DNMT1 is a major DNA methyltransferase that methylates
cytosine residues in the CpG dinucleotides of the genome19, 20. It
maintains the CpG DNA methylation patterns in the newly
synthesized DNA strands during semi-conservative DNA repli-
cation to preserve epigenetic inheritance19. DNMT1 is highly
regulated during cell cycle progression and is essential for
embryonic development, monoallelic expression of genomic
imprinted genes, silencing of retrotransposons, X-chromosome
inactivation, heterochromatin structure, and tissue
speciﬁcation20, 21. Recent studies revealed that the mono-
methylation of DNMT1 by SET7 at lysine 142 (K142) triggers the
destruction of DNMT1 protein18. Notably, the methylation of
K142 in human DNMT1 by SET7 is prevented by AKT1-
mediated phosphorylation of serine 143 (S143)22. Similarly, the
monomethylation of E2F1, a critical transcription factor that
regulates the expression of many genes required for S phase
progression, on lysine 185 (K185) by SET7 also triggers the
proteolysis of the E2F1 protein, which is abolished when the cells
are treated with DNA damage agents such as doxorubicin or
etoposide15. However, how the methylated lysine residues in
these proteins are recognized and processed remains unclear.
The cullin-RING ubiquitin ligases (CRLs) comprise the largest
families of ubiquitin E3 ligases23. The CRLs employ a large class
of substrate-speciﬁc receptors to target speciﬁcally modiﬁed
protein substrates for ubiquitin-dependent proteolysis. While
many CRL1 ubiquitin ligases, composed of cullin1 (CUL1), SKP1,
and one of the F-box proteins, recognize phosphorylated protein
substrates, CRL2VHL binds and targets substrates that are marked
by proline-hydroxylation for proteolysis23, 24. However, the
mechanism by which methylation-mediated proteolysis triggered
by SET7 remains unclear25. We and others have previously
shown that the CRL4 core complex, composed of CUL4A (or its
paralogue CUL4B), RBX1 (ROC1), and DDB1, employs a speciﬁc
set of WD40 domain-containing proteins, including the DCAFs,
as the substrate-speciﬁc subunits to form various CRL4-DCAF
ubiquitin E3 ligase complexes in a modular fashion26–31. Each of
these CRL4-DCAF complexes binds and targets speciﬁc protein
substrates for ubiquitin-dependent proteolysis. Here, we report
that the methylated DNMT1 protein is speciﬁcally recognized by
a novel methylation-binding protein, which further recruits a
unique CRL4 ubiquitin E3 ligase to target DNMT1 for ubiquitin-
dependent proteolysis. We also ﬁnd that the methylation-
dependent degradation of E2F1 is controlled by the same
mechanism. Our studies thus reveal a novel and common
mechanism by which the stability of many methylated non-
histone proteins are regulated.
Results
LSD1 demethylates the methylated K142 in DNMT1 to stabi-
lize DNMT1. We have found that treatment of human colorectal
carcinoma HCT116 cells with a speciﬁc inhibitor for LSD1
(KDM1A)32, 33, a demethylase that was originally identiﬁed for its
ability to remove mono- and dimethylated groups from methy-
lated H3K434, induced rapid downregulation of DNMT1 protein
(Fig. 1a). Recent reports indicated that human DNMT1 protein is
monomethylated by SET7 at lysine 142 (K142) and this methy-
lation triggers the degradation of DNMT1 protein18, 22. In mouse
embryonic stem (ES) cells, it was reported that loss of LSD1,
which demethylates the lysine 1096 (K1096, equivalent to human
K1094), also triggers the proteolysis of the mouse DNMT1 pro-
tein35. LSD1 also acts as a demethylase to remove the methyl
group from the monomethylated K185 in E2F1 to stabilize E2F1
protein15. As the R-S-K peptide motif surrounding K142 in
DNMT1 resembles the methylation consensus motif, R/K-S/T-K,
that is present in many SET7-methylated proteins such as the
methylated K4 in histone H3 (H3K4), K372 in p53, and K185 in
E2F1 (Fig. 1b)8, 10, 15, 18, 22, we tested whether LSD1 acts through
the monomethylated K142 in DNMT1 by converting K142 to
Alanine (K142A) and examined whether the K142 mutant is still
sensitive to LSD1 inhibition. While the ectopically expressed
wild-type DNMT1 protein was downregulated after LSD1 was
inhibited, the K142A mutant was resistant to LSD1 inhibition
(Fig. 1c). To effectively detect the methylated K142 in DNMT1,
we developed a speciﬁc anti-monomethylated K142 (K142me)
peptide antibody for DNMT1 (Supplementary Figure 1A), which
only recognized the monomethylated K142 peptide but not the
unmethylated cognate peptide. This antibody also detected the
increased level of monomethylated K142 in wild-type DNMT1
when SET7 is co-expressed in vivo (Supplementary Figure 1B),
which is abolished by the K142A mutation. Our studies also
revealed that the recombinant LSD1 can directly and efﬁciently
demethylate the monomethylated K142 peptide in vitro (Fig. 1d).
To verify the effect of LSD1 inhibitor, we conducted the siRNA-
mediated knockdown of LSD1 in HCT116 cells and found that
while the ectopically expressed wild-type DNMT1 protein was
downregulated when LSD1 is knocked down, the K142A mutant
was resistant to the loss of LSD1 (Fig. 1e). However, we found
that conversion of human K1094 to arginine (K1094R) did not
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signiﬁcantly stabilize DNMT1 in LSD1 knockdown cells (Fig. 1f).
Our studies indicate that LSD1 acts as a demethylase to remove
the methyl group from the methylated K142 in DNMT1 to pre-
vent the methylation-dependent proteolysis of DNMT1 in vivo.
The CRL4 ubiquitin ligase complex is required for DNMT1
degradation. To further investigate how the methylated DNMT1
protein is degraded after LSD1 inactivation, we tried to identify
the ubiquitin E3 ligase that mediates this process. Since CRLs
represent the largest families of ubiquitin E3 ligases, we used
siRNA-mediated knockdown analyses to test the potential
involvement of CRLs in DNMT1 degradation. Our initial screen
of CRL ubiquitin E3 ligases revealed that downregulation of the
components of the CRL4 core complex, consisting of CUL4A or
CUL4B, and DDB1, can block the proteolysis of DNMT1 trig-
gered by the loss of LSD1 (Fig. 2a). Treatment of cells with
MLN9424, an inhibitor of the neddylation of CRLs, including
CRL4, also stabilized DNMT1 in LSD1 knockdown cells (Sup-
plementary Figure 1D). We also found that knockdown of DDB1
blocked the degradation of the methylated DNMT1 protein after
the loss of the AKT1 kinase, which prevents SET7-mediated K142
methylation by phosphorylating S14322 (Fig. 2b). Since ubiquitin
E3 ligases usually directly interact with their protein substrates,
we tested and found that the endogenous CUL4A or CUL4B
interacts with DNMT1 (Fig. 2c). Our studies also revealed that
the interaction of DNMT1 with CUL4A and CUL4B was abol-
ished by the K142A mutation (Fig. 2d), These studies suggest that
the CRL4 ubiquitin E3 ligase complex may be involved in the
K142 methylation-dependent degradation of DNMT1.
DCAF5 serves as a speciﬁc subunit of CRL4 for DNMT1
degradation. The CRL4 ubiquitin E3 ligases usually use one of
substrate-speciﬁc subunit proteins, such as DCAFs, to interact
with speciﬁc protein substrates to target them for degradation26–
31. To further identify the substrate-speciﬁc subunit protein of
CRL4 for DNMT1, we tried to isolate the DNMT1 protein
complex and search for additional CRL4 components. We used a
HCT116 cell line in which the C terminus of one of the DNMT1
alleles is fused with the Flag-epitope-tag (Flag-DNMT1 knock-in)
to facilitate the puriﬁcation of the endogenous DNMT1 protein
complexes by anti-Flag antibody afﬁnity chromatography36
(Fig. 3a). The proteins associated with the puriﬁed DNMT1
complexes were identiﬁed by an Orbitrap XL mass spectrometry
system28, 37. While a large number of DNMT1-derived peptides
were recovered, we repeatedly identiﬁed a small number of
peptides derived from CUL4B, DDB1 and DCAF5, a CRL4-
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Fig. 1 Regulation of DNMT1 proteolysis by LSD1 demethylase. a Inhibition of LSD1 leads to downregulation of DNMT1. HCT116 cells were treated with
dimethyl sulfoxide (DMSO) or 50 μM LSD1 inhibitor CBB1003 for 12 h and DNMT1 and LSD1 protein levels were analyzed by blotting with indicated
antibodies. Actin was used as a loading control. Molecular weight markers are indicated. Experiments were repeated three independent times (biological
replicates) with the same conclusion and one example is shown. b The conserved lysine residues (K*) methylated by SET7 in a methylation motif with the
R/K-S/T-K* consensus sequences in histone H3, p53, DNMT1 and E2F1. c The K142A mutant of DNMT1 is resistant to LSD1 inhibition. HCT116 cells were
transiently transfected with the Flag-tagged wild-type (WT) or K142A mutant of DNMT expression constructs for 48 h. They were treated with DMSO or
50 μM LSD1 inhibitor as in Fig. 1a. The cells were directly lysed in an SDS-containing lysis buffer and Flag-DNMT1, endogenous LSD1 and actin (loading
control) were detected by respective antibodies. d LSD1 demethylates the methylated K142 in DNMT1. 1 μg of control GST or GST-LSD1 proteins were
incubated with 100 ng of monomethylated K142 or unmethylated peptides for 2 h and the resulting peptides were blotted onto nitrocellulose membrane.
The demethylated products were detected by anti-monomethylated K142 antibodies. Total peptides were monitored by anti-DNMT1 antibodies. e Loss of
LSD1 destabilizes DNMT1 through K142. HCT116 cells were transiently transfected with the Flag-tagged DNMT1 or K142A mutant expression constructs
for 12 h. They were then transfected with 50 nM siRNAs of luciferase (Luc, control) or LSD1 for additional 48 h. The cells were processed as in c. f The
K1094R mutant is still sensitive to LSD1 inactivation. HCT116 cells were transiently transfected with the Flag-tagged DNMT1 (WT) or K1094R mutant for
48 h. They were then transfected with 50 nM siRNAs of luciferase (Luc, control) or LSD1 and processed as in e. All experiments from c, f were repeated
three independent times with the same conclusion
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associated DCAF with unknown function, in the DNMT1 protein
complexes (Fig. 3a and Supplementary Table 1).
Since the CRL4 core complex is involved in DNMT1
degradation (Fig. 2), we tested whether DCAF5 is indeed
associated with the DNMT1 complexes. Our independent
immuno-co-precipitation analyses conﬁrmed the interactions
between the endogenous DNMT1 and DCAF5 proteins (Fig. 3b
and Supplementary Figure 1E). We also functionally tested the
involvement of DCAF5 in DNMT1 degradation. While reduction
of LSD1 triggers the proteolysis of DNMT1, co-knockdown of
DCAF5 using two independent DCAF5 siRNAs and LSD1 siRNA
consistently prevented the degradation of endogenous DNMT1
protein (Fig. 3d). Since it was reported that the K142-methylated
DNMT1 is protected by the binding of PHF20L138, an MBT-
Tudor domain-containing protein encoded by a putative
oncogene that is ampliﬁed or over-expressed in aggressive breast
cancers39, we knocked down PHF20L1 and found there is
increased degradation of DNMT1, and this degradation is also
prevented by co-knockdown of DCAF5 (Fig. 3e). Our subsequent
analysis showed that the interaction between DNMT1 and
DCAF5 is greatly enhanced when SET7 is ectopically expressed
(Fig. 3c). These studies revealed that CRL4DCAF5 is likely involved
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Fig. 2 CRL4 regulates the protein stability of DNMT1. a Loss of CRL4 core components stabilizes DNMT1. HCT116 cells were transfected with 50 nM
siRNAs for each of luciferase, CUL4A+CUL4B (CUL4A/B), and DDB1 for 48 h, in the presence or absence of LSD1 siRNA as indicated. The levels of
DNMT1 and CRL4 proteins were analyzed by blotting with indicated antibodies on the left. The protein samples were analyzed with three replicate repeats
and the proteins bands were quantiﬁed and normalized to the luciferase siRNA control. The quantiﬁcations were represented by bar graph with mean and
standard deviation (S.D.) for error bars from three replicates. The P value of LDS1 to control (Luc) siRNAs was calculated by independent Student’s t-test
and the P values of double to single knockdowns were calculated by paired Student’s t-test (*P < 0.05, **P < 0.01). Experiments were repeated three
independent times with the same conclusion. b Loss of DDB1 stabilizes DNMT1 in AKT1 knockdown cells. HCT116 cells were transfected with 50 nM
siRNAs for Luc or DDB1, in the presence or absence of AKT1 siRNA as indicated for 48 h. The proteins were analyzed and quantiﬁed as in a. Student’s t-test
was used for signiﬁcant differences. *P < 0.05, ***P < 0.001. c The endogenous CRL4 core complexes interact with DNMT1. Endogenous protein complexes
were immunoprecipitated (IP) with indicated antibodies and blotted with anti-DNMT1, CUL4A, CUL4B, or CUL4CT (detecting the C termini of CUL4A and
CUL4B) antibodies. Non-speciﬁc IgG was used as a control. Experiments were repeated four independent times with the same conclusion. d CRL4 binding
to DNMT1 is abolished by K142A mutation in DNMT1. HCT116 cells were transiently transfected with the Flag-tagged DNMT1 (WT) or K142A mutant
constructs for 48 h. The cells were lysed and proteins were immunoprecipitated by anti-CUL4A/CUL4B antibodies or control IgG. The proteins in the CRL4
complexes were detected by anti-Flag and anti-CUL4A/CUL4B antibodies. Experiments were repeated three independent times with the same conclusion
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in the methylation-dependent degradation of DNMT1 catalyzed
by SET7.
L3MBTL3 is involved in DNMT1 degradation. In histones,
methylated lysine residues are usually recognized by distinct
methylation-binding proteins with the Chromo-, Tudor-, MBT-,
and PHD-domains1, 4, 6, 7. During the puriﬁcation of DNMT1
protein complexes, we have also noticed the presence of peptides
derived from L3MBTL3 (Fig. 3a and Supplementary Table 1), a
protein that contains the three tandem repeated malignant brain
tumor (MBT) domain. L3MBTL3 was previously isolated as an
accessory component of Polycomb Repressive Complex 1 (PRC1)
40, 41. L3MBTL3 is mutated in medulloblastoma and is further
implicated in other pathological disorders such as multiple
sclerosis, insulin resistance, prostate cancer and breast cancer42–
46. Other MBT domain-containing proteins, such as L3MBTL1
and L3MBTL2, were reported to bind to mono- or dimethylated
lysine residues in histones to induce chromatin compaction or
transcriptional repression6, 46. Although the function of
L3MBTL3 remains unknown, mouse null mutation of L3MBTL3
causes late embryonic lethality47.
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Since CRL4DCAF5 does not appear to contain a recognizable
methylation-binding domain, we tested whether L3MBTL3 is
involved in DNMT1 degradation (Fig. 4). Our independent
veriﬁcation conﬁrmed that endogenous DNMT1 and L3MBTL3
proteins indeed reciprocally associated with one another (Fig. 4a).
In addition, co-silencing of L3MBTL3 using two independent
siRNAs, together with LSD1 or PHF20L1 siRNAs, showed that
downregulation of L3MBTL3 stabilized endogenous DNMT1
protein in LSD1 or PHF20L1 deﬁcient cells (Fig. 4b, c,
Supplementary Figure 2A, 2B). To rule out the potential
a
e
d
b
g
c
f
0
0.2
0.4
SiRNA: Lu
c
LS
D1
L+
L3
MB
TL
3-1
L+
DC
AF
5-1
***
**
**
L3
MB
TL
3-1
0.6
0.8
1.0
1.2
1.4
0
0.2
0.4
0.6
0.8
1.0
SiRNA :
R
el
at
iv
e 
L3
M
BT
L3
bo
un
d 
DN
M
T1
Luc Set7
***
0
0.2
0.4
0.6
0.8
1.0
1.2
SiRNA: Lu
c
LS
D1
L3
MB
TL
3
L+
L3
MB
TL
3
PH
F2
0L
1
P+
L3
MB
TL
3R
el
at
iv
e 
m
R
N
A 
le
ve
l
o
f D
NM
T1
0
2
4
6
8
10
**
SiRNA:
R
el
at
iv
e 
L3
M
BT
L3
bo
un
d 
DN
M
T1
Luc PHF20L1
L3MBTL3
IP:
DNMT1
α-
DN
MT
1
IgG α-L
3M
BT
L3
_ 100
_ 250
SiRNA: Lu
c
LS
D1
L+
L3
MB
TL
3-1
L3
MB
TL
T3
-1
DNMT1
LSD1
L3MBTL3
Actin
Lu
c
LS
D1
L+
L3
MB
TL
3-2
L3
MB
TL
3-2
_
_
_
_
250
100
100
55
Actin
L3MBTL3
PHF20L1
DNMT1
SiRNA: Lu
c
PH
F2
0L
1
P+
L3
MB
TL
3-1
L3
MB
TL
3-1
_
_
_
_
250
130
100
55
Flag-DNMT1
L3MBTL3
LSD1
Actin
L+
DC
AF
5-1
Lu
c
LS
D1
L+
L3
MB
TL
3-1
L3
MB
TL
3-1
SiRNA:
_
_
_
_
100
100
250
55
SiRNA: Lu
c
Se
t7
Lu
c
Se
t7
DNMT1
L3MBTL3
Set7
Actin
Lysates IP: L3MBTL3
_
_
_
_
250
100
55
55
Actin
PHF20L1
L3MBTL3
DNMT1
SiRNA: Lu
c
PH
F2
0L
1
Lu
c
PH
F2
0L
1
Lysates IP:L3MBTL3
_
_
_
_
250
100
130
55
kDa
kDa
kDa kDa
kDa
kDa
Fig. 4 L3MBTL3 regulates DNMT1 protein stability. a Interaction between DNMT1 and L3MBTL3. DNMT1 and L3MBTL3 were immunoprecipitated from
HCT116 cells and western blotted with their respective antibodies. b Loss of L3MBTL3 stabilizes DNMT1 in LSD1 deﬁcient cells. HCT116 cells were
transfected with luciferase and two independent L3MBTL3 siRNAs in the presence or absence of LSD1 siRNA for 48 h. Proteins were analyzed by indicated
antibodies. c Downregulation of L3MBTL3 prevents DNMT1 degradation in PHF20L1 knockdown cells. Experiments were conducted as in Fig. 4b except
PHF20L1 siRNA is used. d Loss of DCAF5 or L3MBTL3 stabilizes Flag-DNMT1 in LSD1 deﬁcient cells. The Flag-DNMT1 in pMSCV-Puro was stably
expressed in 293 cells and its protein stability was analyzed after transfecting either L3MBTL3 or DCAF5 siRNAs, together with or without LSD1 siRNA as
in Fig. 2a, using Student’s t-test for signiﬁcant differences. **P < 0.01 and ***P < 0.001. e Loss of L3MBTL3 does not signiﬁcantly affect DNMT1 mRNA
levels. The DNMT1 mRNA levels were measured in triplicated samples in cells treated with siRNAs for Luciferase, LSD1, PHF20L1, L3MBTL3, LSD1
+L3MBTL3, and PHF20L1+L3MBTL3 by RT–qPCR. The quantiﬁcations are represented by bar graph with mean and standard deviation (S.D.) for error bars
from three replicate samples and normalized to luciferase siRNA control. f Downregulation of SET7 reduces the interaction between DNMT1 and L3MBTL3.
HCT116 cells were transfected with control and SET7 siRNAs and the interaction between DNMT1 and L3MBTL3 was analyzed by immunoprecipitation and
western blotting. Signiﬁcant differences was calculated by Student’s t-test, as in Fig. 2a. ***P < 0.001. g Downregulation of PHF20L1 promotes the
interaction between DNMT1 and L3MBTL3. HCT116 cells were transfected with control and PHF20L1 siRNAs for 48 h. The proteasome inhibitor (5 μg/ml)
MG132 was added for last 6 h to stabilize DNMT1 for analyzing and quantifying the levels of the interaction between DNMT1 and L3MBTL3. Student’s t-
test was calculated, as in Fig. 2a, for signiﬁcant differences. **P < 0.01. Quantiﬁcations for all experiments were represented by bar graph with mean and S.
D. for error bars from three replicates, as described in Fig. 2a. All experiments were repeated three independent times with the same conclusion
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04019-9
6 NATURE COMMUNICATIONS |  (2018) 9:1641 | DOI: 10.1038/s41467-018-04019-9 | www.nature.com/naturecommunications
regulation of DNMT1 by L3MBTL3 at the transcriptional level,
we ectopically and stably expressed a Flag-tagged DNMT1
protein under the retroviral LTR promoter control in 293 cells
and found that downregulation of LSD1 also destabilized the
ectopically expressed Flag-DNMT1 protein, but the degradation
of Flag-DNMT1 is prevented by the knockdown of L3MBTL3 or
DCAF5 (Fig. 4d), indicating that L3MBTL3 and DCAF5 regulate
DNMT1 at the protein level. Our examination of the mRNA
levels of DNMT1 by the reverse transcriptional quantitative PCR
(RT–qPCR) analyses also indicated that loss of L3MBTL3 did not
signiﬁcantly affect DNMT1 transcription (Fig. 4e). These studies
suggest that L3MBTL3 is speciﬁcally and functionally required for
DNMT1 proteolysis triggered by LSD1 or PHF20L1 deﬁciency.
L3MBTL3 speciﬁcally interacts with the monomethylated K142
in DNMT1. Since L3MBTL3 contains the MBT repeated domain
that is considered as a “reader” of various mono- or dimethylated
lysine residues6, 46, we examined whether the interaction between
DNMT1 and L3MBTL3 is affected by the methylated K142 status.
We found that downregulation of SET7, which monomethylates
K142, signiﬁcantly reduced the interaction between DNMT1 and
L3MBTL3 (Fig. 4f), whereas knockdown of PHF20L1 (in the
presence of MG132, an inhibitor of the 26S proteasome, for 6
ﬁnal hours), which binds the methylated K142 and protects
methylated DNMT1 from degradation, greatly enhanced their
association (Fig. 4g). In addition, while expression of SET7-
stimulated the interaction between L3MBL3 and DNMT1, the
K142A mutant cannot interact with L3MBTL3, even in the pre-
sence of SET7 (Fig. 5a). The expression of SET7 speciﬁcally
increased the level of monomethylated K142 in DNMT1, which
can be detected by our anti-monomethylated K142 antibody
(Fig. 5b). We found that this increased methylation in K142
promoted the interaction between DNMT1 and L3MBTL3
(Fig. 5a, b). However, these SET7-dependent methylation pro-
cesses were abolished by the K142A mutation (Supplementary
Figure 1B, Fig. 5a, b). These studies suggest that the interaction
between L3MBTL3 and DNMT1 involves the methylation of
K142 by SET7.
To determine whether L3MBTL3 speciﬁcally binds to the
monomethylated K142 in DNMT1, we analyzed the afﬁnity of
L3MBTL3 in cell lysates toward a pair of DNMT1 peptides (24
amino acid residues and an extra cysteine at the C terminus) that
contain either a monomethylated K142 or a cognate non-
methylated K142 control peptide immobilized by covalent
disulﬁde linkage to Sepharose resins through the C-terminal
cysteine residue at the end of the peptides48 (Fig. 5c). Our analysis
revealed that endogenous L3MBTL3 protein from
HCT116 soluble cell lysates preferentially binds to the mono-
methylated K142 peptide (Fig. 5c). To determine whether
L3MBTL3 can directly bind to the methylated K142 peptide, we
constructed a recombinant fusion protein between glutathione-S-
transferase (GST) and L3MBTL3. We found that the puriﬁed
recombinant GST-L3MBTL3 protein directly and preferentially
binds to the monomethylated K142 peptide in vitro (Fig. 5d),
while other MBT domain containing proteins, such as GST-
L3MBTL1 and GST-L3MBTL2, showed no signiﬁcant bindings,
as compared with that of GST protein control, to the
unmethylated or monomethylated peptide resins (Supplementary
Figure 2C). The MBT domain of L3MBTL3 contains three
tandem MBT repeats and previous studies suggest that the second
MBT repeat usually plays a critical role in L3MBTL3 or related
MBT domain-containing proteins for binding to the methylated
peptides6. We tested the MBT domain of L3MBTL3 in their
binding to the methylated K142 peptide by converting Aspartate
381 to Asparagine (D381N), a critical amino acid residue in the
second MBT repeat of L3MBTL3 for methylated lysine binding6.
As shown in Fig. 5d, the GST-D381N mutant form of L3MBTL3
failed to interact with the monomethylated K142 peptide.
We also expressed the HA-tagged wild-type L3MBTL3 and the
D381N mutant by transfecting into cells and analyzed their
interaction with DNMT1. Our studies revealed that the D381N
mutant of L3MBTL3 greatly reduced its afﬁnity to bind DNMT1
(Fig. 5e). Our studies thus strongly indicate that L3MBTL3
directly and speciﬁcally recognizes and binds to the monomethy-
lated K142 in DNMT1 through its MBT domain.
L3MBTL3 interacts with DCAF5 to target DNMT1 for poly-
ubiquitination. Since L3MBTL3 is a protein that “reads” the
methylated K142 in DNMT1 (Figs. 4 and 5) and since
CRL4DCAF5 also regulates the proteolysis of DNMT1 (Figs. 2 and
3), L3MBTL3 may act as a methylation binding protein to recruit
the CRL4DCAF5 ubiquitin ligase to target the methylated DNMT1
protein for proteolysis through its interaction with CRL4DCAF5.
Several lines of evidence support this model. We found that
downregulation of either DCAF5 or L3MBTL3 led to the accu-
mulation of the monomethylated DNMT1 (Fig. 6a). The inter-
actions between DNMT1 and DCAF5 or L3MBTL3 were
stimulated by SET7 but abolished by the K142A mutation
(Figs. 3c, 5a, b and 6c). Endogenous L3MBTL3 indeed interacted
with the endogenous DCAF5 and DDB1 proteins (Fig. 6b, Sup-
plementary Figure 1F). Furthermore, downregulation of
L3MBTL3 greatly reduced the interaction between DCAF5 and
DNMT1 (Fig. 6d). Our studies also revealed that while it is often
difﬁcult to detect the preferential binding of DCAF5 to the
methylated K142 peptide beads, expression of L3MBTL3 pro-
motes the preferential binding of DCAF5 to the monomethylated
K142 peptide (Fig. 6e).
We also characterized the interaction between DCAF5 and
L3MBTL3. L3MBTL3 contains three conserved domains: the
MBT repeats, a conserved zf-C2 domain with unknown function,
and a SAM (Sterile Alpha Motif) domain for oligomerization of
SAM domain-containing proteins49 (Fig. 7a). We found that
while the full length L3MBTL3 (780 amino acid residues)
interacts with DCAF5 (Fig. 7a, b and Supplementary Figure 3A),
the region between 610–700 amino acid residues in L3MBTL3 is
both necessary and sufﬁcient to interact with DCAF5. Our
analysis also revealed that the carboxyl-terminal region of DCAF5
is required for the interaction with L3MBTL3, independent of the
amino-terminal WD40 repeated domain of DCAF529 (Supple-
mentary Figure 3B). Thus, our studies indicate that L3MBTL3
and DCAF5 interact with each other through speciﬁc protein
regions in these two proteins.
Consistent with the interaction between L3MBTL3 and
DCAF5, our studies further showed that while expression of
L3MBTL3 or DCAF5 can induce weak polyubiquitination of
DNMT1 in 293 cells, co-expression of DCAF5 and L3MBTL3, in
the presence of CRL4 core complex and SET7, greatly stimulated
the polyubiquitination reaction of DNMT1 protein and this effect
was abolished by K142A mutation in DNMT1 (Fig. 6f). These
studies demonstrate that L3MBTL3 recruits the CRL4DCAF5
ubiquitin E3 ligase complex to interact with the methylated
K142 in DNMT1 and consequently targets the DNMT1 protein
for polyubiquitination-dependent proteolysis.
The methylation-dependent DNMT1 proteolysis is cell cycle
regulated. DNMT1 normally maintains the epigenetic inheri-
tance of DNA methylation patterns by methylating cytosine
residues in the CpG dinucleotides of the genome on the newly
replicated DNA strands in S phase18, 22. It also interacts with
other regulatory or epigenetic modulatory proteins independent
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of its DNA methyltransferase activity50–54. We found that the
methylation levels of the DNMT1 protein are higher in S phase
cells arrested by aphidicolin, a DNA polymerase inhibitor, than
that of asynchronously growing HCT116 cells (Fig. 8a), whereas
DNMT1 in G1 cells, released from mitotic shake-off after treat-
ment of microtubule inhibitor nocodazole55, has a lower content
of K142 methylation (Fig. 8b). Since G1 cells usually take about
9–10 h to progress from late mitotic phase to the end of G1
phase26, 55, we have tested the effects of LSD1 or PHF20L1
knockdown in early and mid-G1 phase cells after their release
from mitotic shake-off. We found that DNMT1 appeared to be
much resistant to the siRNA-mediated knockdown of LSD1 in
G1 cells (0–8 h, Fig. 8c). In contrast, the protein level of DNMT1
in G1 cells was reduced if PHF20L1 was knockdown by speciﬁc
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siRNAs in the parallel experiments (Fig. 8d), even these cells
contain relatively low levels of the methylated DNMT1 (Fig. 8b).
Our studies further revealed that S phase is a major cell cycle
phase that the protein stability of DNMT1 is dynamically
regulated. In cells synchronized at the G1/S border by sequential
treatment with thymidine and aphidicolin26, we found that
knockdown of LSD1 caused a dramatic downregulation of
DNMT1 between 4–8 h, with a peak at about 6 h, after cells
being released from the G1/S border (Fig. 8e), while DNMT1
appeared less sensitive to LSD1 deﬁciency in both early S phase
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(0–4 h) and late S or early G2 phase (8-10 h) cells. PHF20L1 also
protected DNMT1 in S phase cells between 0 and 8 h after
releasing from the G1/S border (Fig. 8f and Supplementary
Figure 2D). The stability of DNMT1 protein became less sensitive
to PHF20L1 knockdown between 8 and 10 h (Fig. 8f, Supple-
mentary Figure 2D).
To analyze the regulation of DNMT1 protein by the
L3MBTL3-CRL4DCAF5 system, we examined whether the methy-
lated DNMT1 protein and its interaction with L3MBTL3 are
regulated in S phase, using PHF20L1 as a comparison, in the cells
synchronized at the G1/S border by thymidine and aphidicolin26.
This is because both PHF20L1 and L3MBTL3 bind to the
methylated K142 but with opposite consequences (Fig. 4c, g)38.
Our results showed that while there were some DNMT1
methylations and the DNMT1-L3MBTL3 interactions in the
arrested cells (0 h), the levels of methylated DNMT1 were
relatively low in early S phase (0–5 h), increased and peaked at
8–9 h, and then started to decline 10–12 h post-release from the
G1/S border (Fig. 8g). There was signiﬁcant binding of PHF20L1
to DNMT1 in arrested cells (0 hour) and in cells between 0 and 9
h after the release. In contrast, there was minimum interaction
between DNMT1 and L3MBTL3 in early S phase cells (0–5 h).
Even when the levels of methylated DNMT1 increased at 8–9 h,
L3MBTL3 binding to DNMT1 was barely detectable, although the
interaction between PHF20L1 and DNMT1 remained signiﬁcant.
However, the binding of L3MBTL3 to DNMT1 became greatly
increased to peak at 10–11 h in late S and early G2 phases,
preceded with the disappearance of PHF20L1 from its association
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Fig. 8 The methylation-dependent proteolysis of DNMT1 is cell cycle regulated. a S phase cells contain higher levels of methylated DNMT1. HCT116 cells
were treated with DMSO or 5 μg/ml aphidicolin for 18 h. Methylated DNMT1 was immunoprecipitated with anti-monomethylated K142 antibodies and
blotted with anti-DNMT1 antibodies. b G1 cells are low in methylated DNMT1. HCT116 cells were treated with DMSO or 40 ng/ml nocodazole for 14 h. The
mitotic round-up cells were collected, washed, and re-plated in fresh medium. The G1 cells were lysed at 7.5 h after re-plating. DNMT1 proteins were
immunoprecipitated by anti-DNMT1 antibodies and blotted by anti-monomethylated K142 and anti-DNMT1 antibodies. c HCT116 cells were transfected
with luciferase and LSD1 siRNAs for 30 h, treated with nocodazole for 14 h, and mitotic rounded-up cells were collected and released into fresh medium, as
in b. The late mitotic, early and mid G1 cells were collected at 0, 5.5, and 8 h. DNMT1, LSD1, cyclin B1 (degraded in G1), and actin were examined by
western blotting. d The same as c except that HCT116 cells were treated with PHF20L1 siRNAs for 30 h, followed by mitotic shake-off and release into G1. e
HCT116 cells were transfected with luciferase and LSD1 siRNAs for 30 h and synchronized at the G1/S border by sequential treatment of 2.5 mM thymidine
and 5 μg/ml aphidicolin. The released S phase cells were collected at indicated time points. The levels of DNMT1, LSD1, cyclin E (high in G1/S and early S)
and actin were analyzed by western blotting. f The same as e except that HCT116 cells were treated with PHF20L1 siRNAs, g HCT116 cells were
synchronized at the G1/S border as in e. Cells were collected at various indicated time points after release and the levels of the K142-methylated DNMT1,
total DNMT1, and their interactions with L3MBTL3 or PHF20L1 were analyzed by immunoprecipitation and western blotting. Quantiﬁcations were
represented by bar graph with mean and standard deviation (S.D.) for error bars from three replicates and experiments were repeated three independent
times with the same conclusion
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with DNMT1 at 10–12 h (Fig. 8g). Total levels of DNMT1 protein
were slightly increased in most of S phase (0–10 h) but became
greatly reduced between 11–12 h after its binding to L3MBTL3
reached the highest levels at 10–11 h. These studies indicate that
the methylation-dependent proteolysis of DNMT1 is cell cycle
regulated by PHF20L1 and L3MBTL3 in S phase and is consistent
with our observation that loss of PHF20L1 reduced DNMT1
protein levels between 0 and 8 h after releasing form the G1/S
border (Fig. 8f). These studies indicate that L3MBTL3 and
PHF20L1 regulate the degradation of the methylated DNMT1
protein in a mutually exclusive manner.
The methylated DNMT1 protein is a critical target of
L3MBTL3 and DCAF5. Although most of our single siRNA
transfection of L3MBTL3 and DCAF5 can achieve about 70–90%
of target protein reduction (Figs. 3d, e and 4b, d), we also found
that re-transfection of the same siRNA to the respective siRNA-
treated cells can achieve more complete depletion of L3MBTL3 or
DCAF5 expression in HCT116 cells (Supplementary Figure 4).
Under these conditions, we repeatedly found that depletion of
L3MBTL3 or DCAF5 alone is sufﬁcient to induce the elevated
level of DNMT1 protein and causes a reduction of proliferating
cell numbers, as compared with that of a non-speciﬁc control
siRNA against luciferase (Supplementary Figure 4). However, co-
depletion of DNMT1, together with either L3MBTL3 or
DCAF5 siRNAs, restored the cell numbers to that of control
siRNA in L3MBTL3 or DCAF5 deﬁcient cells (Supplementary
Figure 4). Since knockdown of L3MBTL3 or DCAF5 induced
elevated levels of methylated DNMT1 protein (Fig. 6a), these
studies suggest that DNMT1 is a critical target of L3MBTL3 and
the CRL4DCAF5 ubiquitin E3 ligase complex and that the elevated
levels of methylated DNMT1 protein impede the growth of
HCT116 cells.
L3MBTL3 and CRL4DCAF5 also regulate the methylated E2F1
proteolysis. The consensus methylated K142 degradation motif
in DNMT1 is present in many other non-histone proteins
including the methylation motif containing lysine 185 (K185) in
E2F1 (Fig. 1b)8, 15, a key transcription factor required for the
expression of S phase genes in the cell cycle. SET7 is known to
monomethylate K185 to trigger E2F1 proteolysis15, which is
abolished by DNA damage or the presence of LSD115. To char-
acterize the regulation of methylated non-histone proteins more
broadly, we tested whether L3MBTL3 and CRL4DCAF5 also reg-
ulate the methylation-dependent proteolysis of E2F1 (Fig. 9). Our
studies revealed that while knockdown of LSD1 reduced E2F1
protein levels, co-silencing of either the components of CUL4D-
CAF5 or L3MBTL3 signiﬁcantly stabilized E2F1 protein in LSD1
deﬁcient cells (Fig. 9a–c, Supplementary Figure 2E, F). We also
found that E2F1 binds to L3MBTL3 and DCAF5, and this
binding was abolished when K185 is converted to Arginine
(K185R), which cannot be methylated by SET7 (Fig. 9d, f).
Expression of both L3MBTL3 and DCAF5 can also greatly sti-
mulate the polyubiquitination of E2F1 protein, which was
diminished in the K185R mutant (Fig. 9g). These studies indicate
that the methylation-dependent polyubiquitination and proteo-
lysis of E2F1 is also regulated by L3MBTL3 and CRL4DCAF5,
similar to that of DNMT1.
Mouse null deletion of L3MBTL3 causes accumulation of
DNMT1 protein. Mouse null mutation of the L3MBTL3 (MBT-1
−/−) gene was reported to impair the maturation of hemato-
poietic system, reduce the expression of genomic imprinted CDK
inhibitor p57Kip2 gene, and cause anemia and late embryonic
lethality around E17.5-E19.547. To determine whether the
deletion of L3MBTL3 in the mouse causes any effects on DNMT1,
we have analyzed the knockout (KO or null) mutation of
L3MBTL3 (MBT-1, −/−) mice. Consistent with the original
report47, we found that deletion of both alleles of the L3MBTL3
(−/−) gene caused visible developmental defects of embryos
around E14-15 and all of the KO mutant embryos died by
E17.5–E19.5 (Fig. 10a). In L3MBTL3 KO mutant embryos,
increased levels of 5’-methylated cytosine in the genomic DNA
and accumulation of DNMT1 protein were observed (Fig. 10a,
Supplementary Figure 5A). Since each L3MBTL3 (+/−) hetero-
zygous breeding pair of female and male mice produces 6–8
embryos, usually only 1–2 L3MBTL3 KO embryos and equal
number of wild-type embryos, together with 3–4 heterozygous
embryos, are produced by such a breeding pair. Our subsequent
studies on the randomized L3MBTL3 KO mutant embryos (N=
7) from 6 different female mice revealed that the protein levels of
DNMT1 were elevated in all of 7 L3MBTL3 KO embryos
(Fig. 10b, c, Supplementary Figure 5), which correlated with the
increased levels of methylated DNA in the same set of 7
L3MBTL3
KO embryos between E14-E15.5 (Fig. 10b, c, Supplementary
Figure 5), as compared with that of wild-type (total N= 7) or
L3MBTL3 heterozygous (−/+ ) embryos in the same litter.
Sometimes, we also observed a slight increase in the methylated
DNA level in the L3MBTL3 heterozygous mutant embryos
(Fig. 10b). Thus, our studies revealed that loss of L3MBTL3 in the
mouse caused the accumulation of DNMT1 protein and increased
levels of methylated DNA. Our ﬁnding should help explain the
defects of L3MBTL3 KO mutation for altered expression of
genomic imprinted genes such as the CDK inhibitor p57Kip2 gene
in the fetal liver and the failure of hematopoietic development
that causes anemia47, as DNMT1 and DNA methylation are
known to play critical roles in regulating genome imprinting and
hematopoietic stem cells and progenitor cells during hemato-
poietic development56, 57.
Discussion
In this report, we found that LSD1 acts as a demethylase that
removes the methyl group from the monomethylated K142 in
DNMT1 to stabilize the protein (Fig. 1). Although the motif
surrounding K142 is highly conserved between human and
mouse DNMT1 proteins, a previous study reported that K1096 in
the mouse DNMT1 protein serves as a substrate of SET7
in vitro35. However, mutation of K1096 in the mouse DNMT1
did not completely abolish methylation of mouse DNMT1 by
SET7, suggesting additional SET7 methylation sites exist in
DNMT1. In addition, the efﬁciency of LSD1 demethylation on
the methylated K1096 was low, maximum at 30% of total K1096-
methylated DNMT1. We found that unlike the K142A mutant,
K1094R did not signiﬁcantly stabilize human DNMT1 protein in
LSD1 knockdown cells (Fig. 1). LSD1 can directly and efﬁciently
demethylate the monomethylated K142 peptide in vitro (Fig. 1d).
Our evidence strongly indicates that the methylated K142 of
DNMT1 is a major substrate for LSD1 demethylase both in vitro
and in vivo.
Increasing evidence indicates that many non-histone proteins
contain the consensus methylation motif, R/K-S/T-K, that are
recognized and methylated by SET78, 12, 13, 17. A recent bio-
chemical study using puriﬁed SET7 recombinant protein revealed
that it can methylate a large number of novel non-histone pro-
teins in vitro11. While these studies show that many non-histone
proteins are methylated by lysine-speciﬁc methyltransferases, very
little is known about how these methylation signals in non-
histone proteins are recognized and processed. In this report, we
have investigated the mechanism by which DNMT1 and E2F1,
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two best-characterized methylated non-histone proteins, are
regulated by methylation-dependent proteolysis. We show that
the methylation-dependent proteolysis of DNMT1 and E2F1 is
regulated by a novel methyl-binding protein, L3MBTL3, and a
previously uncharacterized ubiquitin E3 ligase, the CRL4DCAF5
complex. Our studies are consistent with a model, as schemati-
cally illustrated in Fig. 10d, that methylated proteins are recog-
nized by the MBT domain of L3MBTL3, which recruits the
CRL4DCAF5 ubiquitin E3 ligase complex, to target the methylated
proteins for ubiquitin-dependent proteolysis.
Our studies further revealed that the methylation-dependent
DNMT1 degradation is highly cell cycle regulated, likely asso-
ciated with its heightened catalytic DNA methylation activities in
S phase and additional epigenetic functions in other cell cycle
phases. In S phase cells, both LSD1 and PHF20L1 protect the
methylated DNMT1 protein by preventing the binding of
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Fig. 9 L3MBTL3 and CRL4DCAF5 regulate the methylation-dependent proteolysis of E2F1. a Downregulation of the CRL4 core complexes stabilized E2F1 in
LSD1 knockdown cells. HCT116 cells were transfected with 50 nM siRNAs for each CRL4 core component, with or without LSD1 siRNA (LSD1 or L). E2F1
and indicated proteins were detected as indicated. Quantiﬁcations were represented by bar graph with mean and S.D. for error bars from three independent
replicates, and Student’s t-test was calculated for signiﬁcant differences, as described in Fig. 2a. *P < 0.05, **P < 0.01 and ***P < 0.001. b Downregulation of
DCAF5 stabilizes E2F1. HCT116 cells were transfected with DCAF5 siRNA with or without LSD1 siRNA as indicated. E2F1, DCAF5, LSD1 and actin were
examined by Western blotting, as in a. c Downregulation of L3MBTL3 prevents E2F1 proteolysis in LSD1 knockdown cells. HCT116 cells were transfected
with control and L3MBTL3 siRNAs with or without LSD1 siRNA. E2F1, L3MBTL3, LSD1 and actin were examined by western blotting. d Ectopically expressed
DCAF5 interacts with E2F1. Lysates from HCT116 cells expressing a stably expressed Flag-HA-DCAF5 were immunoprecipitated and blotted with indicated
anti-HA and E2F1 antibodies. e L3MBTL3 and E2F1 interact with each other. Endogenous L3MBTL3 and E2F1 proteins were immunoprecipitated from
HCT116 cells and western blotted with anti-E2F1 and L3MBTL3 antibodies as indicated. f The interaction between L3MBTL3 and E2F1 is dependent on the
presence of K185 in E2F1. The Flag-wild-type E2F1 and Flag-K185R mutant expression constructs were transfected into HCT116 cells with or without SET7
expression as indicated. The interactions between L3MBTL3 and Flag-E2F1 or its K185R mutant were analyzed by anti-Flag and anti-L3MBTL3
immunoprecipitation and western blotting. Input: total cell lysates. g L3MBTL3 and CRL4DCAF5 ubiquitin E3 ligase complexes target E2F1 for
polyubiquitination. Flag-E2F1 or Flag-K185R mutant expressing constructs were co-transfected into 293 cells together with vectors expressing HA-tagged
ubiquitin (HA-Ub), SET7, CUL4A, CUL4B, and DDB1, in the presence or absence of L3MBTL3 and DCAF5 expressing constructs as indicated. The
transfected proteins were immunoprecipitated with anti-Flag antibodies and Western blotted with anti-E2F1 antibodies. Experiments were repeated three
independent times with the same conclusion
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L3MBTL3 to DNMT1. Upon the dissociation of PFH20L1 and
possibly reduced LSD1 activities, L3MBTL3 binds to the methy-
lated DNMT1 to target it for the L3MBTL3-dependent proteo-
lysis in late S and G2 phases. The dual protection mechanisms of
LSD1 and PHF20L1 ensure that the methylation and degradation
of DNMT1 protein is tightly regulated by the L3MBTL3-
CRL4DCAF5 system in the cell cycle. Notably, DNMT1 and
E2F1 are also known to form a protein complex with HDAC1 and
Rb53, and degradation of both proteins for gene expression by the
L3MBTL3-CRL4DCAF5 complex may be warranted.
Methods
Cell culture. HCT116 cells and 293 cells were purchased from ATCC and cultured
in RPMI-1640 or DMEM medium supplemented with 10% fetal bovine serum and
1% antibiotics (Invitrogen). The cells have been recently authenticated and tested
negative for contamination based on the pseudo diploid genome for HCT116 cells
and protein markers for both HCT116 and 293 cells. HCT116-Flag-DNMT1
knock-in cells were kindly provided by Dr. Zhenghe Wang (Case Western Reserve
University) in which one of two DNMT1 gene alleles was C-terminally tagged by
the Flag epitope sequence36. All cells were negative for the mycoplasma tests. For
stable expression, human DNMT1, L3MBTL3, and DCAF5 cDNAs were cloned
into the retroviral pMSCV-3XFlag-3XHA vector (Clontech) to construct the
amino-terminal tagged 3XFlag-3XHA fusion proteins. Transient transfection for
recombinant viral packaging was conducted in 293 cells using the calcium phos-
phate method30. The recombinant viruses were collected from cell culture media of
transfected cells and were used to infect HCT116 or 293 cells. Cells with stable
expression of targeted proteins were selected by the puromycin resistance32, 37.
Expression of target proteins was conﬁrmed by western blotting analyses. Lipo-
fectamine 2000 was used for other transient expression constructs into HCT116 or
293 cells such as the expression of the DNMT1 K142A mutant and in vivo poly-
ubiquitination analyses32.
Cell cycle synchronization. For synchronization of cells at the G1/S border, active
growing HCT116 cells were treated with 2.5 mM thymidine for 18 h, released into
fresh cell culture medium for 9 h, and then treated again with 5 μg/ml aphidicolin
(Sigma) for another 15 h to synchronously arrest the cells at the G1/S border26–28.
Cells were washed with the phosphate-buffered saline (PBS) and released into fresh
culture medium for S phase entry. For synchronization in mitosis using the mitotic
shake-off method, actively growing HCT116 cells were treated with 40 ng/ml
nocodazole for 14 h and the round-up mitotic cells were shaken off the culture
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Fig. 10 Effects of L3MBTL3 null mutation in mouse embryos and a model for the degradation of methylated proteins. a Deletion of mouse L3MBTL3 gene is
embryonic lethal. The mouse wild-type (WT) and L3MBTL3 null (−/−, KO) mutant embryos at embryonic day 14 (E14) after breeding. The genomic DNA
from two wild-type and the KO embryos were extracted and used for genome-typing and 40 ng of the genomic DNA from each embryo was heat
denatured, spotted onto the Genescreen membrane, and blotted with the anti-5-methylcytosine antibody (5mC) using the Methylene Blue staining as the
loading control. b The levels of DNMT1 protein and methylated DNA increased in L3MBTL3 KO mutants. The mouse wild-type (WT), heterozygous (HET),
and L3MBTL3 null (KO) mutant embryos at E15.5 from the same female mouse were used to analyze the levels of DNMT1 protein and methylated genomic
DNA as indicated, with anti-DNMT1 and anti-5mC antibodies. c The relative methylated DNA content in L3MBTL3 wild-type (+/+, N= 7) and KO (−/−,
N= 7) mutant embryos from 6 different female mice between E14 and E15.5 was examined and compared. Statistically signiﬁcant differences between
means of methylated DNA levels in wild-type and knockout mutants were compared using two-tailed equal-variance independent Student’s t-test. *P <
0.05. The levels of methylated DNA in the wild-type embryos were normalized and set as 1.0. Quantiﬁcations were represented by bar graph with mean
and standard deviation (S.D.) for error bars from 7 L3MBTL3 KO embryos (N= 7) containing the elevated methylated DNA, which also correlated with the
increased levels of DNMT1 protein in these KO embryos (please see Supplementary Figure 5 for more examples). d A schematic model for the ubiquitin-
dependent proteolysis of the methylated R/K-S/T-K motif-containing proteins by L3MBTL3 and CRL4DCAF5 ubiquitin E3 ligase complexes. The lysine
residue (red and bold K) within the consensus R/K-S/T-K motif is dynamically methylated or demethylated by SET7 or LSD1, respectively. The
monomethylated lysine residue (red and bold Kme) is recognized by the MBT domain of L3MBTL3. L3MBTL3 further interacts with the CRL4DCAF5
ubiquitin E3 ligase complex to target the methylated protein substrates for polyubiquitination-dependent proteolysis
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dishes, collected by centrifugation, and washed extensively with PBS to remove
nocodazole26, 55. The cells were re-plated in fresh culture medium without the
drug. The cells usually attached to the plates within 1–3 h after exit of mitosis to
enter into the G1 phase, which is about 10–12 h.
Antibodies and immunological analysis. Anti-LSD1 (A300-215A), L3MBTL3
(A302-852), DNMT1 (A300-041A), SET7 (A301-747A), and DDB1 (A300-462A)
antibodies were purchased from Bethyl Laboratories; anti-PHF20L1 (HPA028417)
were from Sigma; anti-E2F1 (KH95), cyclin E (HE12), cyclin B1 (GNS1), and actin
(Sc-1616) antibodies were from Santa Cruz Biotechnologies. The anti-5-
methycytosine monoclonal antibody (33D3, A-1014-050) was from Epigentek.
Anti-CUL4A and CUL4B, Flag, HA, and GST antibodies were described
before28, 32, 37. The monomethylated K142 (PLSKPRTPRRSKme1SDGEAKPC)
and cognate unmethylated peptides of DNMT1, as well as a DCAF5 peptide
(MKRRAGLGGSMRSVVGFLSQRGLHC) were synthesized at Selleck Chemicals.
The monomethylated K142 peptide and DCAF5 peptide were used to raise rabbit
polyclonal antibodies after coupling these peptides to keyhole limpet hemocyanin
(KLH)26–28. For direct western blotting, the cells were washed with PBS and
directly lysed in the 2XSDS sample buffer (4% SDS, 100 mM Tris, pH6.8, and 20%
glycerol). Protein concentrations were measured by the protein assay dye (Bio-Rad)
and equalized before addition of 0.2% bromophenol blue, freshly added 10% beta-
mercaptoethanol, and boiled for 15 min. Usually three replicate repeats of siRNA-
based knockdown experiments were conducted to evaluate the effects on target
proteins. Each set of protein samples in a siRNA-based knockdown experiment
were normalized by total proteins to the luciferase siRNA control and further
analyzed by western blotting analysis in three replicates to normalize protein levels
to the protein loading controls such as actin to evaluate knockdown efﬁciencies,
effects on target proteins, and operational variables. The antibodies for western
blotting were: anti-LSD1, CUL4A, CUL4B, HA, GST, Flag, and 5meC antibodies
diluted at 1:2000; anti-L3MBTL3, DNMT1, SET7, DDB1, cyclin B1 and cylcin E
antibodies at 1:1000; anti-PHF20L1 and E2F1 antibodies at 1:300, and anti-actin
antibodies at 1:600026–28. For immunoprecipitation, cells were lysed with the
NP40-containing lysis buffer (0.5% NP40, 50 mM Tris, pH 7.5, 150 mM NaCl, and
protease inhibitors, aprotinin, trypsin inhibitor, leupeptin, and benzamindine)26–
28. Lysates were cleared by centrifugation and the proteins in the cell lysates were
quantiﬁed by the protein assay dye (Bio-Rad). Usually 500 μg of lysates were used
for each immunoprecipitation assay48. The antigen–antibody complexes were then
pulled down by 30 μl Protein A-Sepharose (GE Healthcare) and speciﬁc proteins
were detected by western blotting analyses26–28, using secondary goat anti-mouse
HRP (Jackson Immuno Research, 115-035-008) and goat–anti-rabbit antibodies
(Jackson Immuno Research, 111-035-008), or Protein A HRP (GE Healthcare,
NA9120V), all at 1:2000 dilutions. The uncropped Western blot images were
included in Supplementary Figure 6-19.
Afﬁnity puriﬁcation of the monomethylated K142 peptide antibodies. The
unmethylated and monomethylated K142 peptides were immobilized to Sulfolink-
coupled-resins (Thermo Fisher) by covalently cross-linking with the cysteine
residues at the end of the peptides to the resin. The anti-monomethylated K142
peptide serum (5 ml) was diluted in 1:1 in PBS and ﬁrst passed through the
unmethylated K142 peptide column (1 ml) to deplete anti-K142 peptide antibodies.
The unbound ﬂow-through antibody fraction was then loaded onto the mono-
methylated K142 peptide column (0.5 ml), washed, and the bound antibody frac-
tion was eluted by 5 ml of 100 mM glycine, pH 2.5. The eluted antibodies (0.5 ml/
fraction) were immediately neutralized by adding 100 μl of 2 M Tris, pH 8.5, and
tested for speciﬁcity toward the monomethylated K142 peptide but not to the
unmethylated K142 peptide26–28.
RT–qPCR analysis. The mRNAs from cells were isolated by the TRIzol kit
(Thermo Fisher Scientiﬁc), reverse-transcribed, and quantiﬁed by real time
quantitative PCR using SYBR green on an ABI Prism 7300 System32, 37. The
primers used for RT–qPCR: GAPDH forward and reverse: GGTAGGGAGTTC-
GAGACCAG and TCAACGCAGTTCAGTTAGGC; DNMT1 forward and reverse:
GCGTTCCGGCTGAACAAC and GCATCTCCACGTCTCCCT. Mouse genotyp-
ing primers ﬂanking the deleted exon of L3MBTL3 (MBT-1) mice:
TCAGTCTGGGCAGTGATGTC and TTGCACACTAAGGAAGGGAAC.
Methylated peptide binding assays. The monomethylated K142 and cognate
unmethylated peptides of DNMT1 were covalently coupled to the Sulfolink-
coupled resins27, 28, 48 (Thermo Fisher) through the disulﬁde bond between the C-
terminal cysteine of the peptides and the resins. The Glutathione-S-transferase
(GST) was fused in frame to the amino-terminus of the full length L3MBTL3 or its
D381N mutant in pGEXKG and the recombinant fusion proteins were expressed in
Escherichia coli and puriﬁed by Glutathione Sepharose (GE Healthcare)26, 27. For
peptide binding assays, 25–30 μl of peptide-coupled resin were prewashed with the
binding buffer (0.1% NP40, 50 mM Tris-Cl, pH 7.5, 150 mM NaCl) and the resins
were pre-blocked with 5 μg GST protein at room temperature for 2 h. The peptide-
coupled resins were then incubated with 1.5 μg each of GST or indicative GST-
fusion proteins in the binding buffer overnight at 4 °C. The beads were extensively
washed (4–5 times) with PBS and the proteins associated with the resins were
analyzed by western blotting with anti-GST antibodies48. In the case of cell lysates
as the source of endogenous L3MBTL3 or DCAF5, HCT116 cells were lysed with
the NP40-containing lysis buffer, cleared nuclear fractions, and 250–500 μg of
soluble cell lysate proteins were used for each peptide resin binding assay48.
Demethylation analysis. The glutathione-S-transferase (GST) and the GST-LSD1
(human) fusion protein were expressed in E. coli BL21 strain and puriﬁed by the
Glutathione Sepharose resin. Puriﬁed 1 μg of control GST or GST-LSD1 proteins
were incubated with 100 ng of the monomethylated K142 or unmethylated control
cognate peptides for 2 h at room temperature and the resulting peptides were
blotted onto nitrocellulose membrane. The demethylated peptides were detected by
immuno-blotting with the afﬁnity puriﬁed anti-monomethylated K142 antibody or
the anti-DNMT1 antibody for total peptides.
Immuno-afﬁnity puriﬁcation and mass spectrometry analysis. Cell lysates from
twenty dishes (150 mm × 25mm) of HCT116 cells containing the knock-in Flag-
DNMT1 or equal dishes of control HCT116 cells were employed for immuno-
afﬁnity puriﬁcation using 1 ml of the anti-Flag M2 afﬁnity gel (Sigma, A2220)28, 37.
The proteins in the Flag-DNMT1 immunocomplexes were separated on an SDS-
PAGE gel. The protein bands were excised and trypsinized. Tryptic peptides
derived from each gel slice were separated by an online C18 (New Objective,
IntegraFritTM Column, ProteoPepTMC18) nano-ﬂow reversed-phase liquid chro-
matography (Easy nano-liquid chromatography) connected to an LTQ Orbitrap
XL mass spectrometer (Thermo Scientiﬁc) at 300 nl/minute with 75 min of linear
gradients from 0 to 35% acetonitrile in 0.1% formic acid. The liquid chromato-
graphy eluent was directly nanosprayed into the LTQ Orbitrap XL mass spectro-
meter with an ionization voltage of 2.2 kV. During the chromatographic separation,
the LTQ Orbitrap XL is operated in a data-dependent mode and under the direct
control of Xcalibur (Thermo Scientiﬁc). The mass spectrometry (MS) data were
acquired using the following parameters: 5 data-dependent collision-induced dis-
sociation MS2 scan survey in the linear ion trap per every full scan in the Orbitrap
with the resolution set to a value of 60,000; 35% normalized collision energy in
CID;±2 Da isolation window. Proteomic data were analyzed by QualBrowser in
Xcalibur and Proteome Discoverer26–28.
Transfection and siRNAs. Oligofectamine (Life Technologies) was used for
transfection of siRNAs into HCT116 or 293 cells for siRNA-mediated knockdown
analysis28, 32. Typically, 50 nM of each siRNA or their combinations were trans-
fected into target cells for 48 h and cells were directly lysed in SDS or NP40 lysis
buffers. The knockdown effects were examined by western blotting with speciﬁc
antibodies. For veriﬁcation of the effects of new proteins, usually 2 or 3 inde-
pendent siRNAs were designed to examine the knockdown efﬁciency and the
consequences of knockdown on target proteins. The siRNAs for human genes are:
CUL4A: CTGCAGAACTGATCGCAAA; CULB: AAGCCUAAAUUACCAGAAA;
DDB1: AGGAAACTTTGAAGAGATT; LSD1: GGAAGAAGAUAGUGAAAAC;
AKT1: GACGGGCACATTAAGATCA; PHF20L1: TGGGGTTGATGGTGCT-
GAA; DCAF5-1: GCUGCAGAAACCUCUACAA; DCAF5-2: ATCAC-
CAACTTCTGACATA; L3MBTL3-1: GATGCAGATTCTCCTGATA; L3MBTL3-
2: GGTACCAACTGCTCAAGAA; SET7: GGGCAGTATAAAGATAACA; and
control siRNA for luciferase: CATTCTATCCTCTAGAGGA. All siRNAs were
synthesized from GE Dharmacon.
Animals. The L3MBTL3 (MBT-1−/+, B6;129-L3mbtl3tm1Tmiy) mice was kindly
provided by Dr. Miyazaki, Tokyo University. They were bred, housed, and handled
in accordance with the animal protocols approved by the institutional IACUC
committee at University of Nevada, Las Vegas. All animals were housed in ﬁlter-
topped cages supplied with irradiated bedding in HEPA-ﬁltered clean room. All
procedures were conducted according to the National Institutes of Health (NIH)
Guide for Care and Use of Laboratory Animals. Before any mouse experiments
were performed, the experimental procedures were approved by the UNLV
Institutional Animal Use and Care Committee (IACUC) and all experiments
complied with all relevant ethical regulations. The UNLV IACUC is an AAALAC
approved facility and meets the NIH Guide for the Care and Use of Animals. For
embryo analyses, usually 3 pairs of the L3MBTL3 (−/+) male and female mice
(10–12 weeks old) in three cages, each with 1 male and 1 female, were bred in the
late afternoon and the breeding plugs were examined in the female mice in next
morning. The positive plugs were counted as embryonic day 1 (E1) and the
pregnant female mice between E14 and E17.5 were killed by the primary method of
CO2 asphyxiation, followed by cervical dislocation (secondary method), as
approved by the institutional IACUC committee. The sample size was chosen on
the basis of our experience on L3MBTL3 mutant mice and on cultured cells in
order to detect the DNMT1 protein for differences of at least 50% between the
wild-type and mutant groups. Usually a single pregnant female mouse produced
about 6–8 embryos, which segregated at the Mendelian ratio, usually with 1–2
L3MBTL3 (−/−), 1–2 wild-type and 3–4 heterozygous L3MBTL3 (−/+) embryos.
In the experimental analyses for examination of protein and methylated DNA
levels, the investigators were unaware of the genotypes of the experimental
embryos. The investigators also randomly analyzed the wild-type, heterozygous
and homozygous knockdown embryos. The L3MBTL3 null embryos between E17.5
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and 19.5 usually died and became disintegrated so they were excluded from protein
analyses.
Analysis of proteins and DNA from embryos. The experimental procedures for
embryo isolation were approved by the UNLV Institutional Animal Use and Care
Committee (IACUC). The embryos were dissected from the killed pregnant female
mice, washed with PBS, and lysed in the NP40 lysis buffer58. The nuclear and
cytosolic fractions were separated by centrifugation. Genomic DNA was isolated
from nuclear pellets by Zymo genomic DNA-tissue prep kit and quantiﬁed. Pro-
teins in the cytosolic suppernant of the lysates were quantiﬁed by protein assay dye
(Bio-Rad), equalized, and boiled for 15 min after addition of 1% SDS and 5% beta-
mercaptoethanol to the lysates. Proteins were resolved in protein gel and analyzed
by western blotting. For detection of methylated DNA, genomic DNA was heat
denatured, dot blotted to the Genescreen membrane (PerkinElmer Life Sciences),
UV cross-linked, and analyzed by the anti-5-methycytosine monoclonal antibody.
Statistical information. Experiments were usually performed with at least three
independent repeats (biological replicates) to ensure the results. Statistical plot
analyses were performed using Microsoft Excel. Protein bands were quantiﬁed
using Image J. To quantify protein loading in each western blot analysis of a set of
protein samples, the same protein samples were analyzed with three repeated
loading experiments (technical replicates). For cell-based assays, triplicated repeats
in the same set of cells (technical replicates) were measured and the experiments
usually repeated in three independent experiments with independently cultured
cells (biological replicates). Quantitative data are expressed by bar graph, with
mean and standard deviation (S.D.) for error bars from independent replicates. For
siRNA-mediated knockdown experiments, statistically signiﬁcant differences or
variations between means of double and single knockdowns were normalized to the
luciferase siRNA control and compared using two-tailed paired Student’s t-test. For
animal experiments, triplicated breeding was used to obtain statistically signiﬁcant
number of embryos; and statistically signiﬁcant differences between means of
protein or methylated DNA levels in the control wild-type and knockout mutants
were compared using two-tailed equal-variance independent Student’s t-test. All
other data were determined using a two-tailed equal-variance independent Stu-
dent’s t-test. The data in all ﬁgures met the assumption of normal distribution for
tests. Different data sets were considered to be statistically signiﬁcant when the P-
value was <0.05 (*), 0.01 (**) or 0.001 (***)59.
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the paper and its supplementary information ﬁles. The
data that support the ﬁndings of this study are also available from the corre-
sponding author upon reasonable request.
Received: 18 September 2017 Accepted: 27 March 2018
References
1. Greer, E. L. & Shi, Y. Histone methylation: a dynamic mark in health, disease
and inheritance. Nat. Rev. Genet 13, 343–357 (2012).
2. Margueron, R. & Reinberg, D. Chromatin structure and the inheritance of
epigenetic information. Nat. Rev. Genet 11, 285–296 (2010).
3. Mosammaparast, N. & Shi, Y. Reversal of histone methylation: biochemical
and molecular mechanisms of histone demethylases. Annu. Rev. Biochem. 79,
155–179 (2010).
4. Klose, R. J. & Zhang, Y. Regulation of histone methylation by
demethylimination and demethylation. Nat. Rev. Mol. Cell, Biol. 8, 307–318
(2007).
5. Jorgensen, S., Schotta, G. & Sorensen, C. S. Histone H4 lysine 20 methylation:
key player in epigenetic regulation of genomic integrity. Nucleic Acids Res 41,
2797–2806 (2013).
6. Nady, N. et al. Histone recognition by human malignant brain tumor
domains. J. Mol. Biol. 423, 702–718 (2012).
7. Lu, R. & Wang, G. G. Tudor: a versatile family of histone methylation
‘readers’. Trends Biochem .Sci. 38, 546–555 (2013).
8. Zhang, X., Wen, H. & Shi, X. Lysine methylation: beyond histones. Acta
Biochim. Biophys. Sin. (Shanghai) 44, 14–27 (2012).
9. Hamamoto, R., Saloura, V. & Nakamura, Y. Critical roles of non-histone
protein lysine methylation in human tumorigenesis. Nat. Rev. Cancer 15,
110–124 (2015).
10. Chuikov, S. et al. Regulation of p53 activity through lysine methylation.
Nature 432, 353–360 (2004).
11. Dhayalan, A., Kudithipudi, S., Rathert, P. & Jeltsch, A. Speciﬁcity analysis-
based identiﬁcation of new methylation targets of the SET7/9 protein lysine
methyltransferase. Chem. Biol. 18, 111–120 (2011).
12. Kim, S. K. et al. SET7/9 methylation of the pluripotency factor LIN28A is a
nucleolar localization mechanism that blocks let-7 biogenesis in human ESCs.
Cell Stem Cell 15, 735–749 (2014).
13. Fu, L. et al. Set7 mediated Gli3 methylation plays a positive role in the
activation of Sonic Hedgehog pathway in mammals. eLife 5, https://doi.org/
10.7554/eLife.15690 (2016).
14. Calnan, D. R. et al. Methylation by Set9 modulates FoxO3 stability and
transcriptional activity. Aging 4, 462–479 (2012).
15. Kontaki, H. & Talianidis, I. Lysine methylation regulates E2F1-induced cell
death. Mol. Cell 39, 152–160 (2010).
16. Yang, J. et al. Reversible methylation of promoter-bound STAT3 by
histone-modifying enzymes. Proc. Natl Acad. Sci. USA 107, 21499–21504
(2010).
17. Yang, X. D. et al. Negative regulation of NF-kappaB action by Set9-
mediated lysine methylation of the RelA subunit. EMBO J. 28, 1055–1066
(2009).
18. Esteve, P. O. et al. Regulation of DNMT1 stability through SET7-mediated
lysine methylation in mammalian cells. Proc. Natl Acad. Sci. USA 106,
5076–5081 (2009).
19. Sharif, J. et al. The SRA protein Np95 mediates epigenetic inheritance by
recruiting Dnmt1 to methylated DNA. Nature 450, 908–912 (2007).
20. Qin, W., Leonhardt, H. & Pichler, G. Regulation of DNA methyltransferase 1
by interactions and modiﬁcations. Nucleus 2, 392–402 (2011).
21. Jones, P. A. & Liang, G. Rethinking how DNA methylation patterns are
maintained. Nat. Rev. Genet 10, 805–811 (2009).
22. Esteve, P. O. et al. A methylation and phosphorylation switch between an
adjacent lysine and serine determines human DNMT1 stability. Nat. Struct.
Mol. Biol. 18, 42–48 (2011).
23. Petroski, M. D. & Deshaies, R. J. Function and regulation of cullin-RING
ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 6, 9–20 (2005).
24. Kaelin, W. G. Jr. & Ratcliffe, P. J. Oxygen sensing by metazoans: the central
role of the HIF hydroxylase pathway. Mol. Cell 30, 393–402 (2008).
25. Yang, Y. & Bedford, M. T. Titivated for destruction: the methyl degron. Mol.
Cell 48, 487–488 (2012).
26. Higa, L. A., Mihaylov, I. S., Banks, D. P., Zheng, J. & Zhang, H. Radiation-
mediated proteolysis of CDT1 by CUL4-ROC1 and CSN complexes
constitutes a new checkpoint. Nat. Cell Biol. 5, 1008–1015 (2003).
27. Higa, L. A. et al. L2DTL/CDT2 interacts with the CUL4/DDB1 complex and
PCNA and regulates CDT1 proteolysis in response to DNA damage. Cell Cycle
5, 1675–1680 (2006).
28. Higa, L. A. et al. CUL4-DDB1 ubiquitin ligase interacts with multiple WD40-
repeat proteins and regulates histone methylation. Nat. Cell Biol. 8, 1277–1283
(2006).
29. Jin, J., Arias, E. E., Chen, J., Harper, J. W. & Walter, J. C. A family of diverse
Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase
destruction of the replication factor Cdt1. Mol. Cell 23, 709–721 (2006).
30. O’Connell, B. C. & Harper, J. W. Ubiquitin proteasome system (UPS): what
can chromatin do for you? Curr. Opin. Cell Biol. 19, 206–214 (2007).
31. Higa, L. A. & Zhang, H. Stealing the spotlight: CUL4-DDB1 ubiquitin ligase
docks WD40-repeat proteins to destroy. Cell Div. 2, 5 (2007).
32. Zhang, X. et al. Pluripotent Stem Cell Protein Sox2 Confers Sensitivity to
LSD1 Inhibition inCancer Cells. Cell Rep. 5, 445–457 (2013).
33. Wang, J. et al. Novel Histone Demethylase LSD1 Inhibitors Selectively Target
Cancer Cells with Pluripotent Stem Cell Properties. Cancer Res. 71, 7238–7249
(2011).
34. Shi, Y. et al. Histone demethylation mediated by the nuclear amine oxidase
homolog LSD1. Cell 119, 941–953 (2004).
35. Wang, J. et al. The lysine demethylase LSD1 (KDM1) is required for
maintenance of global DNA methylation. Nat. Genet 41, 125–129 (2009).
36. Du, Z. et al. DNMT1 stability is regulated by proteins coordinating
deubiquitination and acetylation-driven ubiquitination. Sci. Signal. 3, ra80
(2010).
37. Yin, F. et al. LSD1 regulates pluripotency of embryonic stem/carcinoma cells
through histone deacetylase 1-mediated deacetylation of histone H4 at lysine
16. Mol. Cell. Biol. 34, 158–179 (2014).
38. Esteve, P. O. et al. Methyllysine reader plant homeodomain (PHD) ﬁnger
protein 20-like 1 (PHF20L1) antagonizes DNA (cytosine-5) methyltransferase
1 (DNMT1) proteasomal degradation. J. Biol. Chem. 289, 8277–8287 (2014).
39. Jiang, Y., Liu, L., Shan, W. & Yang, Z. Q. An integrated genomic analysis of
Tudor domain-containing proteins identiﬁes PHD ﬁnger protein 20-like 1
(PHF20L1) as a candidate oncogene in breast cancer. Mol. Oncol. 10, 292–302
(2016).
40. Zhang, J. et al. SFMBT1 functions with LSD1 to regulate expression of
canonical histone genes and chromatin-related factors. Genes Dev. 27,
749–766 (2013).
41. Lin, S. et al. Proteomic and functional analyses reveal the role of chromatin
reader SFMBT1 in regulating epigenetic silencing and the myogenic gene
program. J. Biol. Chem. 288, 6238–6247 (2013).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04019-9
16 NATURE COMMUNICATIONS |  (2018) 9:1641 | DOI: 10.1038/s41467-018-04019-9 | www.nature.com/naturecommunications
42. Northcott, P. A. et al. Multiple recurrent genetic events converge on control of
histone lysine methylation in medulloblastoma. Nat. Genet. 41, 465–472
(2009).
43. Kar, S. P. et al. Genome-wide meta-analyses of breast, ovarian, and prostate
cancer association studies identify multiple new susceptibility loci shared by at
least two cancer types. Cancer Discov. 6, 1052–1067 (2016).
44. Andlauer, T. F. et al. Novel multiple sclerosis susceptibility loci implicated in
epigenetic regulation. Sci. Adv. 2, e1501678 (2016).
45. Lotta, L. A. et al. Integrative genomic analysis implicates limited peripheral
adipose storage capacity in the pathogenesis of human insulin resistance. Nat.
Genet. 49, 17–26 (2017).
46. Bonasio, R., Lecona, E. & Reinberg, D. MBT domain proteins in development
and disease. Semin. Cell Dev. Biol. 21, 221–230 (2010).
47. Arai, S. & Miyazaki, T. Impaired maturation of myeloid progenitors in mice
lacking novel Polycomb group protein MBT-1. EMBO J. 24, 1863–1873
(2005).
48. Tsvetkov, L. M., Yeh, K. H., Lee, S. J., Sun, H. & Zhang, H. p27(Kip1)
ubiquitination and degradation is regulated by the SCF(Skp2) complex
through phosphorylated Thr187 in p27. Curr. Biol. 9, 661–664 (1999).
49. Kim, C. A. & Bowie, J. U. SAM domains: uniform structure, diversity of
function. Trends Biochem. Sci. 28, 625–628 (2003).
50. Clements, E. G. et al. DNMT1 modulates gene expression without its catalytic
activity partially through its interactions with histone-modifying enzymes.
Nucleic Acids Res. 40, 4334–4346 (2012).
51. Easwaran, H. P., Schermelleh, L., Leonhardt, H. & Cardoso, M. C. Replication-
independent chromatin loading of Dnmt1 during G2 and M phases. EMBO
Rep. 5, 1181–1186 (2004).
52. Ha, K. et al. Rapid and transient recruitment of DNMT1 to DNA double-
strand breaks is mediated by its interaction with multiple components of the
DNA damage response machinery. Hum. Mol. Genet. 20, 126–140 (2011).
53. Robertson, K. D. et al. DNMT1 forms a complex with Rb, E2F1 and HDAC1
and represses transcription from E2F-responsive promoters. Nat. Genet. 25,
338–342 (2000).
54. Jin, B. et al. DNMT1 and DNMT3B modulate distinct polycomb-mediated
histone modiﬁcations in colon cancer. Cancer Res. 69, 7412–7421 (2009).
55. Lan, R. et al. Dissecting the phenotypes of Plk1 inhibition in cancer cells using
novel kinase inhibitory chemical CBB2001. Lab. Invest. 92, 1503–1514 (2012).
56. Smith, Z. D. & Meissner, A. DNA methylation: roles in mammalian
development. Nat. Rev. Genet. 14, 204–220 (2013).
57. Trowbridge, J. J., Snow, J. W., Kim, J. & Orkin, S. H. DNA methyltransferase 1
is essential for and uniquely regulates hematopoietic stem and progenitor cells.
Cell Stem Cell 5, 442–449 (2009).
58. Shim, E. H. et al. Expression of the F-box protein SKP2 induces hyperplasia,
dysplasia, and low-grade carcinoma in the mouse prostate. Cancer Res. 63,
1583–1588 (2003).
59. Fay, D. S. & Gerow, K. A biologist’s guide to statistical thinking and analysis.
WormBook: the online review of C. elegans biology, 1-54, https://doi.org/
10.1895/wormbook.1.159.1 (2013).
Acknowledgements
We thank Drs Toru Miyazaki and Satoko Arai (Tokyo University) for the MBT-1
deletion mouse and Dr. Zhenghe Wang (Case Western Reserve University) for the Flag-
tagged-DNMT1 HCT116 cells. This work was supported by grants from National
Institutes of Health (R15NS096694 to HS and R15GM116087 to HZ) and from the
Cancer Research Gift Fund to the College of Sciences at University of Nevada, Las Vegas
(to both HS and HZ).
Author contributions
H.Z. perceived the conception, organized approaches, designed and supervised all
research activities, analyzed results, and wrote the manuscript; F.L. designed and con-
ducted most experiments; J.Y. and H.Z. performed the mass spectrometry-based pro-
teolysis and data analysis, C.Z., S.A., N.H., H.S., and F.Lu, assisted in some experiments.
All authors read and agreed on the manuscript drafted by H.Z.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
018-04019-9.
Competing interests: The authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2018
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04019-9 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:1641 | DOI: 10.1038/s41467-018-04019-9 | www.nature.com/naturecommunications 17
